drugset / Trial / NCT02223416

A Study Aimed at Assessing the Pharmacokinetic Properties of RGB-10 and Forsteo

NCT02223416

Phase 1 Completed Gedeon Richter Plc.

Summary

Pharmacokinetic properties, safety and tolerability of RGB-10 and Forsteo will be compared in healthy female volunteers.

Timeline

Start
Primary completion
2015-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject RGB-10 Unknown
Comparator Teriparatide Protein / enzyme biologic

Indications

No indication recorded.